The S1P1 receptor, which is among the most highly and ubiquitously expressed members of the large family of G protein--coupled receptors ([@bib41]), provides basic cell functions that include survival, migration, adhesion, and proliferation ([@bib50]; [@bib4]; [@bib24]). The receptor binds the lysophospholipid sphingosine-1-phosphate (S1P), triggering signaling cascades coupled to the G~i~ pathway.

The S1P1 receptor is one of five S1P receptors. Within the immune system, S1P receptor signaling has several roles in the regulation of innate and adaptive immune responses ([@bib12]; [@bib46]; [@bib16]; [@bib44]). The S1P1 receptor has been shown to control lymphocyte egress from the thymus ([@bib32]; [@bib3]), spleen ([@bib10]; [@bib32]), and lymph nodes ([@bib32]). The importance of the S1P1 receptor in this process was initially recognized by the demonstration that immunosuppressant compounds that trapped lymphocytes in lymph nodes and the thymus were ligands for multiple S1P receptors ([@bib5]; [@bib30]). It was later shown that S1P1 receptor--deficient lymphocytes were not competent to exit the thymus and lymph nodes, demonstrating the importance of the S1P1 receptor in mediating lymphocyte egress from these lymphoid tissues ([@bib32]; [@bib3]).

The lipid ligand S1P is ubiquitously synthesized but largely degraded in most tissues, resulting in low ligand levels in lymphoid tissues and higher concentrations in blood and lymph ([@bib51]). The S1P concentration differential is believed to drive lymphocyte egress from lymphoid tissues to blood and lymph via stimulation of the lymphocyte S1P1 receptor ([@bib28]; [@bib51]; [@bib38]).

Although the S1P1 receptor has been shown to provide a mandatory egress signal for lymphocyte emigration from the thymus, lymph nodes, and spleen, a similar role for the S1P1 receptor in the transfer of newly formed, immature B cells from the bone marrow into the periphery has not been described, nor is this emigration process well understood. However, it is known that newly formed immature B cells transit from the bone marrow parenchyma through the endothelium and into the sinusoids, where they are temporarily retained until their release into the general circulation ([@bib37]; [@bib33]; [@bib39]). In this paper, we show that these immature B cells require the S1P1 receptor for their efficient appearance in the bone marrow vascular compartment and peripheral blood. Furthermore, the expression on bone marrow B cells of CD69, an S1P1 receptor--interacting protein that modifies thymic and lymph node egress of lymphocytes by lowering S1P1 receptor levels on their cell surface ([@bib53]), also negatively modulates the appearance of immature B cells in peripheral blood. These results provide new details about the process of immature B cell release from the bone marrow by identifying the S1P1 receptor as a key regulator of this process.

RESULTS
=======

Expression of S1P receptors by bone marrow B cells
--------------------------------------------------

We determined the expression of the five members of the S1P receptor family in bone marrow B cells by real-time quantitative PCR (RT-qPCR). Bone marrow B cells were sorted into four populations: (1) B220^+^ IgM^−^ IgD^−^ (pro--/pre--); (2) B220^+^ IgM^+^ IgD^−^ and (3) B220^+^ IgM^+^ IgD^low^ (immature); and (4) B220^+^ IgM^+^ IgD^high^ (mature, recirculating) B cells. *S1pr1* expression increased as differentiation progressed in bone marrow B cells, showing that *S1pr1* is regulated during the development of bone marrow B cells ([Fig. 1 A](#fig1){ref-type="fig"}, control). *S1pr3* and *S1pr4* transcripts were also found on developing bone marrow B cells ([Fig. 1, C and D](#fig1){ref-type="fig"}), whereas *S1pr2* and *S1pr5* were expressed at very low levels ([Fig. 1, B and E](#fig1){ref-type="fig"}).

![**Expression of S1P receptors in bone marrow B cell subpopulations.** (A--E) mRNA expression for *S1pr1* (A), *S1pr2* (B), *S1pr3* (C), *S1pr4* (D), and *S1pr5* (E) in sorted B cell subpopulations from control and B-*S1pr1*KO bone marrow was determined by real-time PCR. Bars represent mean values ± SD from three experiments (*n* = 3 mice per genotype). \*\*, P \< 0.01 (Student\'s *t* test).](JEM_20092210_GS_Fig1){#fig1}

Generation and characterization of B cell--specific *S1pr1* KO (B-*S1pr1*KO) mice
---------------------------------------------------------------------------------

To study the role of the S1P1 receptor in B cells, we deleted the *S1pr1* gene specifically in B cells using the Cre/loxP system. We bred mice bearing the loxP-flanked *S1pr1* allele ([@bib1]) with mice carrying the *Cre* recombinase gene under the transcriptional control of the endogenous *CD19* promoter ([@bib43]) to obtain mice homozygous for the floxed *S1pr1* allele and carrying the *Cre* transgene, termed B-*S1pr1*KO mice. In the *CD19-Cre* mice, the Cre recombinase expression has been detected in pre--, immature, and mature B cells in bone marrow and the spleen ([@bib52]). To determine the magnitude and specificity of the *S1pr1* gene deletion in the B-*S1pr1*KO mice, we measured the levels of *S1pr1* mRNA by RT-qPCR. Splenic B cells isolated from the B-*S1pr1*KO mice showed a substantial reduction of *S1pr1* mRNA expression compared with those from control mice, whereas mRNA levels in the thymus and brain were unchanged, confirming the B cell specificity of the Cre-mediated deletion (unpublished data). To verify the onset of S1P1 receptor deletion during B cell development, we analyzed the mRNA levels in sorted bone marrow pro--/pre-- (B220^+^ IgM^−^ IgD^−^), immature (B220^+^ IgM^+^ IgD^−^ and B220^+^ IgM^+^ IgD^low^), and mature (B220^+^ IgM^+^ IgD^high^) B cell populations and found that *S1pr1* expression was highly reduced in pro--/pre--, immature, and mature B cells in the B-*S1pr1*KO mice compared with control mice ([Fig. 1 A](#fig1){ref-type="fig"}), consistent with Cre-mediated *S1pr1* deletion occurring by the pre--B cell stage in the B-*S1pr1KO* mice. There were no compensatory increases of *S1pr2*, *3*, *4*, or *5* transcript levels in the B-*S1pr1*KO bone marrow B cell populations ([Fig. 1, B--E](#fig1){ref-type="fig"}).

B220^+^ B cells were quantified in the bone marrow, blood, spleen, and peripheral LNs (PLNs) of the B-*S1pr1*KO mice relative to controls ([Fig. 2, A and B](#fig2){ref-type="fig"}). Overall, total B220^+^ cell numbers in B-*S1pr1*KO mice were normal in the bone marrow and PLNs but were significantly decreased in the spleen and peripheral blood. In blood, spleen, and PLNs, the number of CD3^+^ T lymphocytes was unchanged ([Fig. 2 B](#fig2){ref-type="fig"}).

![**Reduced numbers of B cells in the blood and spleens of B-*S1pr1*KO mice.** (A and B) Flow cytometry analysis of B220^+^ B cells and CD3^+^ T cells in peripheral tissues from 8--12-wk-old B-*S1pr1*KO and control mice. Lymphocytes from the bone marrow, peripheral blood, spleens, and PLNs from control and B-*S1pr1*KO mice were analyzed by flow cytometry using FITC-conjugated anti-B220 and PE-conjugated anti-CD3 antibodies. Results are shown as histograms (A) and the absolute number of cells counted (B) in each organ or per microliter of peripheral blood. In B, bars represent mean values of pooled data, and the closed circles are individual mice. Data are pooled from two to four experiments. \*, P \< 0.05; \*\*\*, P \< 0.005 (Student\'s *t* test).](JEM_20092210_GS_Fig2){#fig2}

Numbers of immature and mature B cells are reduced in the blood and spleen of B-*S1pr1*KO mice
----------------------------------------------------------------------------------------------

Analysis of the bone marrow lineage B cells in B-*S1pr1*KO mice revealed normal numbers of pro--/pre-- and immature B cells, defined by expression of B220, IgM, and CD43, with a significant deficiency in the small population of mature, recirculating B cells (B220^high^ IgM^+^; [Fig. 3, A--D](#fig3){ref-type="fig"}).

![**Reduced numbers of mature and immature B cells in the blood of B-*S1pr1*KO mice.** (A--D) Bone marrow B cell subpopulations from control and B-*S1pr1*KO mice were analyzed by flow cytometry using FITC-conjugated anti-B220, APC-conjugated anti-IgM, and PE-conjugated anti-CD43 antibodies. Pro--/pre--B cells were identified as B220^low^ IgM^−^, immature B cells were identified as B220^low^ IgM^+^, and mature B cells were identified as B220^high^ IgM^+^. Pro--B cells were identified as B220^low^ IgM^−^ CD43^+^ and pre--B cells were identified as B220^low^ IgM^−^ CD43^−^. Results are shown as density plots (A and C) and as the absolute number of cells counted per femur (B and D). The percentage of cells in each gate is indicated on the plots. Bars represent mean values of pooled data from two experiments, and the closed circles are individual mice. \*, P \< 0.05 (Mann-Whitney test). (E--L) B cells from the peripheral blood of control and B-*S1pr1*KO mice were analyzed by flow cytometry. Immature B cells were identified as B220^+^ IgD^low^ IgM^high^ (E and F), B220^+^ CD93^+^ (G and H), B220^+^ CD23^low^ IgM^high^ (I and J), and B220^+^ CD21^low^ IgM^high^ (K and L). Mature B cells were identified as B220^+^ IgD^high^ IgM^low^ (E and F), B220^+^ CD23^high^ IgM^low^ (I and J), and B220^+^ CD21^high^ IgM^low^ (K and L). Results are expressed as a density plot (E, G, I, and K) and the absolute number of cells counted per microliter of peripheral blood (F, H, J, and L). \*, P \< 0.05; \*\*\*, P \< 0.005 (Mann-Whitney test). Data in F, H, J, and L are mean values representative of three independent experiments.](JEM_20092210_RGB_Fig3){#fig3}

The peripheral blood, which normally contains immature B cells (B220^+^ IgM^high^ IgD^low^) recently released from the bone marrow along with recirculating mature B cells (B220^+^ IgM^low^ IgD^high^), was significantly deficient in both of these B cell populations in B-*S1pr1*KO mice ([Fig. 3, E and F](#fig3){ref-type="fig"}). Similar results were obtained with B cell maturation markers CD93, CD23, and CD21 ([Fig. 3, G--L](#fig3){ref-type="fig"}). Immature B cell numbers in the blood of *S1pr1^loxP/+^* mice were similar irrespective of the presence of the *CD19-Cre* transgene ([Fig. S1](http://www.jem.org/cgi/content/full/jem.20092210/DC1)), showing that Cre expression alone did not reduce the appearance of immature B cells in the blood.

In the spleen, the numbers of immature (B220^+^ IgM^high^ IgD^low^) and mature (B220^+^ IgM^low^ IgD^high^) B cells as defined by surface Ig markers were both reduced in B-*S1pr1*KO mice compared with controls ([Fig. S2, A and B](http://www.jem.org/cgi/content/full/jem.20092210/DC1)). Follicular B cells, which are characterized by B220^+^ CD21^int^ CD23^high^ expression (Fig. S2, C and D), were also found to be present in lower numbers in the spleens of B-*S1pr1*KO mice compared with controls. Immunostained frozen sections of spleen tissue confirmed the reduction of B cells relative to T cells in the follicles of B-*S1pr1*KO mice compared with controls (Fig. S2 E). The numbers of marginal zone B cells, defined as B220^+^ CD21^high^ CD23^low^, were slightly but significantly reduced in the B-*S1pr1*KO mice compared with controls (Fig. S2 D). By histological evaluation, their absence was noted in the marginal zone regions (Fig. S2 F). Earlier studies using chimeras reconstituted with fetal liver from *S1pr1*-deficient embryos have shown that the S1P1 receptor on B cells was required for their proper positioning within the marginal zone, but did not note a decrease in total marginal zone B cell numbers ([@bib10]). In agreement with the flow cytometric data ([Fig. 2](#fig2){ref-type="fig"}), the B cell compartment appeared relatively normal in PLNs from B-*S1pr1*KO mice by histological analysis (Fig. S2 G).

Apoptosis is elevated in *S1pr1*-deficient immature B cells in the bone marrow
------------------------------------------------------------------------------

The deficiency of immature B cells in the blood and spleen could be explained by the inefficient release of newly formed B cells into the peripheral blood from their developmental niche in the bone marrow. To further evaluate this possibility, we labeled rapidly proliferating B cells with a pulse of BrdU and, after 48 h, determined the numbers of BrdU-labeled B cells in the bone marrow and peripheral blood ([Fig. 4, A--D](#fig4){ref-type="fig"}). Within the bone marrow, the fraction of B cells labeled with BrdU was similar in the B-*S1pr1*KO and control mice, with no significant labeling differences observed between pro--/pre-- (B220^low^ IgM^−^) and immature B cell populations (B220^low^ IgM^+^; [Fig. 4, A and B](#fig4){ref-type="fig"}). However, the total number of BrdU^+^ B220^+^ cells in the blood from the B-*S1pr1*KO mice was significantly lower than in control mice, with lower numbers of BrdU^+^ immature (B220^+^ IgM^high^ IgD^low^) and mature (B220^+^ IgM^low^ IgD^high^) B cells observed ([Fig. 4, C and D](#fig4){ref-type="fig"}).

![**Immature B cells in the bone marrow do not efficiently enter blood and have elevated apoptosis in the absence of S1P1 receptor.** (A--D) Mice were pulsed with BrdU, and B cells from the bone marrow (A and B) and peripheral blood (C and D) of control and B-*S1pr1*KO mice were analyzed by flow cytometry using anti-B220, anti-IgD, and anti-IgM antibodies in combination with BrdU detection methodology, as described in Materials and methods. Results are shown as dot plots (A and C), and as absolute numbers of BrdU^+^ B220^low^ IgM^−^ (pro--/pre--) and B220^low^ IgM^+^ (immature) B cells per femur (B) and BrdU^+^ B220^+^ IgD^low^ IgM^high^ (immature) and B220^+^ IgD^high^ IgM^low^ (mature) B cells per 400 µl of blood (D). The percentage of cells in each gate is indicated on the plots. Bars represent mean values, and the closed circles are individual mice. Data are representative of three experiments with three to five mice of each genotype per experiment. \*, P \< 0.05; \*\*, P = 0.01 (Student\'s *t* test). (E and G) In vivo staining of bone marrow sinusoidal B cells. Mice were injected intravenously with PE-conjugated anti-CD45.2 antibody. After 2 min, the bone marrow cells and peripheral blood were obtained and stained with PerCP-conjugated anti-B220, APC-conjugated anti-IgM, and FITC-conjugated anti-IgD antibodies. Results are shown as histograms (E) and as the percentage of CD45.2-PE^+^ (sinusoidal cells; G) for pro--/pre-- (B220^+^ IgD^−^ IgM^−^), immature (B220^+^ IgM^+^ IgD^−^ and B220^+^ IgM^+^ IgD^low^), and mature (B220^+^ IgM^+^ IgD^high^) bone marrow B cells from control and B-*S1pr1KO* mice. On the histograms (E), the bars show the percentage of PE-CD45.2^+^ cells for each group. (F) Lymphocytes stained in the peripheral blood by injection of PE-conjugated anti-CD45.2 antibody, showing equal staining in control and B-*S1pr1KO* mice. (H) Cells that were negative for anti-CD45.2--PE antibody staining were considered as parenchymal cells. Results are shown as mean values of four independent experiments (*n* = 10--12 mice per genotype). \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.005 (Mann-Whitney test). (I and J) Annexin V staining was determined on B cells from the bone marrow of control and B-*S1pr1*KO mice. Results are shown as density plots (I) and as the percentage (J) of annexin V^+^ PI^−^ B220^low^ IgM^−^ (pro--/pre--) and B220^low^ IgM^+^ (immature) B cells per femur. Pooled data are from five experiments (*n* = 9 for each genotype). \*\*\*, P \< 0.005 (Mann-Whitney test). (K and L) Annexin V staining on sinusoidal and parenchymal immature B cells. Cells were labeled in vivo with PE-conjugated anti-CD45.2 antibody and gated as in E and H. Annexin V staining was determined on immature bone marrow B cells (B220^+^ 7-AAD^−^ IgM^+^ IgD^−^ and B220^+^ 7-AAD^−^ IgM^+^ IgD^low^) partitioned into parenchymal cells (CD45.2^−^; K) and sinusoidal cells (CD45.2^+^; L) from control and B-*S1pr1KO* mice. Pooled data are from three experiments (*n* = 8 for each genotype). \*, P \< 0.05 (Mann-Whitney test).](JEM_20092210_RGB_Fig4){#fig4}

Upon leaving the bone marrow parenchyma, immature B cells pass through an endothelial barrier and enter the blood sinusoids, where they are retained before finally being released into the peripheral blood. To enumerate the bone marrow parenchymal and sinusoidal B cells, we used in vivo antibody labeling ([@bib15]; [@bib42]; [@bib39]) that entails intravenous injection of PE-conjugated anti-CD45.2 antibody to selectively label hematopoietic cells in the vascular compartment. By applying this technique to B-*S1pr1*KO and control mice, we found that the pro--/pre--B cells were minimally labeled, as they were in the parenchyma, and shielded from the circulating antibody ([Fig. 4, E--H](#fig4){ref-type="fig"}). In contrast, lymphocytes in the peripheral blood were equally well labeled in both control and B-*S1pr1*KO mice ([Fig. 4 F](#fig4){ref-type="fig"}). A portion of each of the immature and mature bone marrow B cell pools was labeled by the injected anti-CD45.2 antibody, representing cells in the sinusoids. The bone marrow B cells that were not labeled by injected anti-CD45.2 antibody were considered to be parenchymal cells. We found that a significantly lower number of immature B cells (B220^+^ IgM^+^ IgD^−^ and B220^+^ IgM^+^ IgD^low^) was labeled by anti-CD45.2 antibody in the B-*S1pr1*KO mice compared with control mice, which is consistent with a defect in immature B cell egress from the bone marrow parenchyma into the sinusoids in S1P1 receptor--deficient mice ([Fig. 4 G](#fig4){ref-type="fig"}). It might have been anticipated that an inability of immature B cells to egress from the bone marrow into sinusoids would result in an increase in the number of total immature B cells in the parenchyma of the B-*S1pr1*KO mice. However, we found similar numbers of bone marrow immature B cells (B220^+^ IgM^+^ IgD^low^) that were CD45.2^−^ in the anti-CD45.2--injected B-*S1pr1*KO and control mice ([Fig. 4 H](#fig4){ref-type="fig"}).

Because we did not detect an accumulation of bone marrow immature cells in the parenchyma of B-*S1pr1*KO mice, we considered the possibility that cells inappropriately retained in bone marrow because of an exit defect might instead undergo cell death. We used annexin V staining to assess the level of apoptosis in the pro--/pre-- and immature B cell populations in the bone marrow of B-*S1pr1*KO mice. Although the annexin V^+^ pro--/pre--B cell fraction was similar in B-*S1pr1*KO and control mice, the immature B cell population showed significantly higher levels of annexin V staining in B-*S1pr1*KO mice than in control mice, indicating an increased incidence of cell death ([Fig. 4, I and J](#fig4){ref-type="fig"}). The numbers of annexin V^−^ immature B cells in total bone marrow and in the parenchymal fraction were similar in the B-*S1pr1*KO and control mice, showing that there was not a deficiency of viable, potentially egress-competent immature B cells because of the deletion of the S1P1 receptor ([Fig. S3, A and B](http://www.jem.org/cgi/content/full/jem.20092210/DC1)).

We next determined if the increased annexin V^+^ fraction of immature B cells was in the parenchymal or sinusoidal cell pools by first labeling cells in the vascular compartment by injection of mice with anti-CD45.2 antibody. There was no difference between B-*S1pr1*KO and control mice in the annexin V staining of the immature cells that were shielded from the anti-CD45.2 antibody (parenchymal cells; [Fig. 4 K](#fig4){ref-type="fig"}). However, there was a significantly higher percentage of annexin V^+^ immature B cells (IgM^+^ IgD^low^) labeled by anti-CD45.2 antibody (sinusoidal cells) in B-*S1pr1*KO mice compared with control mice ([Fig. 4 L](#fig4){ref-type="fig"}). These results indicate that *S1pr1*-deficient immature bone marrow B cells, in contact with the vascular compartment, undergo elevated apoptosis.

S1P1 receptor deficiency does not alter the migration of bone marrow B cells to S1P
-----------------------------------------------------------------------------------

S1P is a chemotactic factor for some B cell types ([@bib10]; [@bib47]; [@bib21]; [@bib11]; [@bib48]) and might directly stimulate migration of immature B cells from bone marrow by its relatively high levels in the blood. This possibility prompted us to determine the potency of S1P as a chemotactic factor for bone marrow B cells from control and B-*S1pr1*KO mice in an in vitro chemotaxis assay. Of pro--/pre--, immature, and mature B cells from control mice, only immature B cells showed a dose response toward S1P. However, this migration response was not significantly different from that of bone marrow B cell populations from the B-*S1pr1*KO mice ([Fig. S4](http://www.jem.org/cgi/content/full/jem.20092210/DC1)). SDF-1 stimulated a migration response in bone marrow B cells that was similar in both types of mice (Fig. S4).

The S1P3 receptor has been shown to play a role in S1P-directed chemotaxis for splenic marginal zone B cells ([@bib10]). Thus, we tested the ability of S1P3 receptor--deficient bone marrow B cells to migrate toward S1P. Interestingly, *S1pr3* KO bone marrow immature B cells migrated significantly less well than WT cells to increasing S1P concentrations ([Fig. 5 A](#fig5){ref-type="fig"}). We next determined the number of immature and mature B cells in the blood and spleen in these KO mice to assess a potential bone marrow exit defect. In blood, there was a significant decrease in immature B cells compared with WT mice ([Fig. 5 C](#fig5){ref-type="fig"}), but this decrease was much less profound than that observed in the blood of B-*S1pr1*KO mice ([Fig. 3 F](#fig3){ref-type="fig"}). Bone marrow and splenic B cells in *S1pr3* KO mice did not show significant changes compared with WT ([Fig. 5, B and D](#fig5){ref-type="fig"}). These data indicate that although the S1P3 receptor is more potent than the S1P1 receptor in mediating an in vitro migration response of immature bone marrow B cells to S1P, the egress defect of immature bone marrow B cells was much more pronounced in B-*S1pr1*KO than in *S1pr3* KO mice.

![**Migration of bone marrow B cells toward S1P is mediated by the S1P3 receptor.** (A) Total bone marrow cells were added to a Transwell insert and allowed to respond to increasing concentrations of S1P or to 100 ng/ml SDF-1 in the lower well. Percentages of the input that were found in the lower well after a 3-h incubation with S1P (left axis) or with SDF-1 (right axis) were plotted for pro--/pre-- (B220^+^ IgD^−^ IgM^−^), immature (B220^+^ IgM^+^ IgD^−^ and B220^+^ IgM^+^ IgD^low^), and mature (B220^+^ IgM^+^ IgD^high^) B cells. Data are presented as mean values ± SD (*n* = 3 for each genotype) and are representative of three independent experiments. \*, P \< 0.05. (B--D) Distribution of B cells in *S1pr3* KO mice. B cell subpopulations from the bone marrow (*n* = 7 per genotype; B), blood (*n* = 10; C), and spleen (*n* = 10; D) from WT and *S1pr3* KO mice were analyzed by flow cytometry using PE-Cy7--conjugated anti-B220, APC-conjugated anti-IgM, and FITC-conjugated anti-IgD antibodies. Results are pooled data from three independent experiments. \*, P \< 0.05.](JEM_20092210_RGB_Fig5){#fig5}

Because adhesion properties of mature B cells can be regulated by S1P1 receptor expression ([@bib18]), we determined the cell-surface expression of CD49d (integrin α4; α subunit of VLA-4), CD49b (integrin α2; α subunit of VLA-2), CD11a (integrin αL; α subunit of LFA-1), and CD62L (L-selectin) on bone marrow B cells, but did not find a difference in the expression of these adhesion molecules between B-*S1pr1*KO and control mice (unpublished data).

CD69 overexpression reduces the number of immature B cells in blood
-------------------------------------------------------------------

CD69, a C-type lectin, was up-regulated on the surface of pro--/pre-- and immature bone marrow B cells in B-*S1pr1*KO mice compared with control mice ([Fig. 6 A](#fig6){ref-type="fig"}), similar to what has previously been described for thymocytes and for mature T and B cells when *S1pr1* was deleted ([@bib32]). In thymocytes, forced overexpression of CD69 blocked egress of maturing T cells from thymus ([@bib25]; [@bib14]; [@bib35]). To determine if CD69 transgenic expression by developing bone marrow B cells also impedes their peripheral blood expression, we established a transgenic mouse line that expressed human CD69 in bone marrow B cells after onset of *CD19-Cre* expression during B cell development ([Fig. 6 B](#fig6){ref-type="fig"} and [Fig. S5 A](http://www.jem.org/cgi/content/full/jem.20092210/DC1)).

![**CD69 expression in bone marrow B cells modulates the appearance of immature B cells in peripheral blood.** (A) CD69 expression on bone marrow B cells. Results are shown as anti-CD69 fluorescence intensity for cells from control and B-*S1pr1*KO mice compared with the isotype control. Representative results are from nine independent experiments. (B) Expression of the human *CD69* transgene on bone marrow total B cells in control and transgenic (CD69-Tg) mice. B220^+^ bone marrow cells were analyzed for their expression of human CD69 by flow cytometry. (C and D) Distribution of B220^low^ IgM^−^ (pro--/pre--) and B220^low^ IgM^+^ (immature) B cells in the bone marrow (C) and of B220^+^ IgD^low^ IgM^+^ (immature) and B220^+^ IgD^high^ IgM^low^ (mature) B cells in the peripheral blood (D) of control and CD69 transgenic mice. Bars represent mean values, and the closed circles are individual mice. Data represent pooled results from three experiments. \*\*, P \< 0.01 (Mann-Whitney test). (E) Annexin V staining on B cells from the bone marrow of control and CD69 transgenic mice. Results are shown as the percentage of annexin V^+^ PI^−^ B220^low^ IgM^−^ (pro--/pre--) and annexin V^+^ PI^−^ B220^low^ IgM^+^ (immature) B cells per femur and represent pooled data from four independent experiments (*n* = 8). \*, P \< 0.05 (Mann-Whitney test). (F--I) Expression of S1P1 receptor on IgM^+^ bone marrow B cells of control and transgenic CD69 mice. IgM^+^ cells were magnetically sorted from total bone marrow cells, fixed, permeabilized, and stained in suspension using a rabbit anti-S1P1 receptor antibody. After incubation with Alexa Fluor 488--conjugated anti--rabbit IgG, the cells were attached to a slide using a cytocentrifuge and visualized by fluorescence microscopy. Bar, 50 µm.](JEM_20092210_RGB_Fig6){#fig6}

Transgenic expression of CD69 had no discernible effect on the number of bone marrow lineage B cells ([Fig. 6 C](#fig6){ref-type="fig"}). However, these transgenic mice showed a decrease in the number of immature and mature B cells in peripheral blood compared with control mice ([Fig. 6 D](#fig6){ref-type="fig"}), which is similar to the observed phenotype for the B-*S1pr1*KO mice ([Fig. 2](#fig2){ref-type="fig"}) and consistent with a bone marrow B cell exit defect. We also detected significantly higher levels of annexin V staining in immature B cell populations in the bone marrow of the CD69 transgenic mice ([Fig. 6 E](#fig6){ref-type="fig"}), suggestive of higher levels of cell death in a manner similar to the S1P1 receptor--deficient bone marrow B cells.

Previous studies have shown that CD69 forms a complex with the S1P1 receptor and that overexpression of CD69 can down-modulate the surface expression of the S1P1 receptor, thereby limiting its signaling activity ([@bib53]). We were unable to determine the S1P1 receptor expression level on the surface of B cells of the CD69 transgenic mice, because there is no antibody available that recognizes an extracellular epitope of the S1P1 receptor on mouse B cells ([@bib28]). However, immunostaining with an antibody that recognizes an intracellular epitope of the S1P1 receptor ([@bib54]) indicated a reduced level of S1P1 receptor expression on IgM^+^ bone marrow cells of the CD69 transgenic mice compared with those of control mice ([Fig. 6, F and G](#fig6){ref-type="fig"}). To confirm that CD69 overexpression negatively regulates S1P1 receptor expression on the cell surface, we also examined S1P1 receptor cellular localization when it was coexpressed with human CD69 in HEK293 cells. When we expressed CD69 in wild-type HEK293 cells, CD69 was localized intracellularly in vesicles and on the plasma membrane (Fig. S5 B). When HEK293 cells stably expressing S1P1-GFP ([@bib27]) were transfected with CD69, S1P1-GFP expression decreased on the plasma membrane and some colocalized with CD69 in intracellular compartments (Fig. S5 C). These data confirm that S1P1 receptor expression on the plasma membrane is down-modulated by CD69 expression.

CXCR4 antagonism does not stimulate the release of developing B cells from bone marrow into the blood of B-*S1pr1*KO mice
-------------------------------------------------------------------------------------------------------------------------

Interaction of the chemokine receptor CXCR4 with its ligand SDF-1 is required for the retention of developing B cells in the bone marrow parenchyma ([@bib34];  [@bib55]; [@bib58]; [@bib29]; [@bib36]; [@bib56]; [@bib39]). When control mice were treated with AMD3100, a potent CXCR4 antagonist ([@bib6]), immature bone marrow B cells (B220^+^ CD93^+^ IgM^+^ IgD^−^ and B220^+^ CD93^+^ IgM^+^ IgD^low^) were released into peripheral blood ([Fig. 7 A](#fig7){ref-type="fig"}). In contrast, the release of immature B cells into blood was significantly lower in B-*S1pr1*KO mice after antagonist treatment ([Fig. 7 A](#fig7){ref-type="fig"}). We did not find an increase of these cells in the spleens in either control or B-*S1pr1*KO mice after antagonist treatment, ruling out that these immature B cells might be trapped in other lymphoid organs (unpublished data). The cell-surface expression of CXCR4 was similar on bone marrow B cells from control and B-*S1pr1*KO mice ([Fig. 7 B](#fig7){ref-type="fig"}). These results indicate that the S1P1 receptor provides a necessary signal for B cell release from the bone marrow when CXCR4 signaling is attenuated.

![**Impaired release of immature bone marrow B cells by CXCR4 antagonism in the absence of S1P1 receptor.** (A) Mice were injected with the CXCR4 antagonist AMD3100 or vehicle alone, and bone marrow and blood were collected after 90 min. Immature bone marrow B cells in the blood (B220^+^ CD93^+^) were gated as IgM^+^ IgD^−^ and IgM^+^ IgD^low^, and quantified from control and B-*S1pr1*KO mice. Results are shown as absolute numbers in 250 µl of blood. Bars represent mean values, and the closed circles are individual mice. Data are representative of three experiments. \*, P \< 0.05 (Mann-Whitney test). (B) CXCR4 expression on pro--/pre-- (B220^low^ IgM^−^) and immature (B220^low^ IgM^+^) bone marrow B cells.](JEM_20092210_RGB_Fig7){#fig7}

DISCUSSION
==========

B cells arise from pluripotent hematopoietic stem cells through a series of developmental stages and selection steps in the bone marrow ([@bib19]; [@bib9]). Niches within the parenchymal extravascular spaces in the bone marrow populated by stromal cells supply factors to support the development and retention of the B cell precursors as they differentiate. Ultimately, the immature cells are released into the peripheral blood circulation to gain access to the spleen, where they reach maturity, whereas some immature B cells recirculate back and mature in the bone marrow ([@bib8]; [@bib26]).

In this paper, we show that S1P1 receptor expression on developing bone marrow B cells is required for their efficient appearance in the sinusoidal blood compartment. Without the signal generated by the S1P1 receptor, immature cells appear to undergo increased apoptosis in the bone marrow while in contact with the vascular compartment. We suggest that the increased cell death observed in S1P1 receptor--deficient mice may be a consequence of the inappropriate retention of the cells within the bone marrow. Developing B cells are known to be exquisitely sensitive to apoptosis ([@bib17]). The immature B cells lacking the S1P1 receptor may be unable to completely transmigrate across the endothelium barrier separating the parenchymal and sinusoidal spaces, or else they may not be released from sinusoids after crossing the endothelium. In either case, inappropriately retained, apoptotic B cells would be in contact with the vascular compartment. Their apoptosis precludes a large accumulation of trapped immature cells or, potentially, their further maturation within the bone marrow ([@bib8]; [@bib26]).

Unlike the effect of the KO of the S1P1 receptor on developing T cells, which caused a nearly complete block in their egress from the thymus and a severe deficiency of mature T cells in the periphery ([@bib2]; [@bib32]), in the present study mature B cells were present in the B-*S1pr1*KO mice, although at reduced numbers in the spleen and at near normal numbers in lymph nodes. Although this finding may have been, in part, the result of incomplete deletion of the S1P1 receptor by the *CD19-Cre* transgene in developing B cells, chimeras generated by transplantation of embryonic liver from *S1pr1*-null embryos also exhibited reduced numbers of B cells in the spleen and peripheral blood, and near normal numbers in lymph nodes ([@bib32]). These findings suggest that the S1P1 receptor requirement for bone marrow egress of B cells is not an absolute one, and that some S1P1 receptor--deficient B cells may escape the bone marrow. Secondary distortion of the peripheral mature B cell compartment in the B-*S1pr1*KO mice may be attributable to homeostatic mechanisms, which sense B cell deficiency ([@bib7]), and the trapping of egress-incompetent S1P1 receptor--deficient B cells in lymph nodes and the spleen ([@bib32]).

The precise mechanism through which the S1P1 receptor controls egress from lymphoid organs has been difficult to pinpoint. Directed lymphocyte chemotaxis to higher concentrations of S1P in blood and lymph has been invoked as one possible means for the S1P1 receptor dependence of egress ([@bib32]); however, we found that in the absence of the S1P1 receptor, bone marrow B cells migrated toward S1P no differently than control cells. Instead, we and others ([@bib13]) found that the S1P-directed migration response of immature bone marrow B cells appeared to be largely mediated by the S1P3 receptor. Even so, B cell emigration out of bone marrow in *S1pr3* KO mice was only slightly affected, based on the number of immature B cells in the blood, when compared with the B-*S1pr1*KO mice. These data suggest that an S1P-directed chemotaxis mechanism, which can be recaptured by the in vitro migration assay, may not be a critical feature of B cell egress from bone marrow. Similarly, a recent study using in vivo imaging along with in vitro analysis of chemotaxis has argued that B cell egress from lymph nodes occurs by a mechanism that is distinct from S1P-mediated chemotaxis ([@bib54]). In this study, and in the case of T cells egressing from lymph nodes, a multistep process that includes an obligatory S1P1 receptor--mediated step for egress has been proposed ([@bib40]). In the bone marrow, the S1P1 receptor on immature B cells may be critical for their transmigration through or release from the endothelium.

SDF-1 stimulates the G~i~-linked G protein--coupled receptor CXCR4 on developing B cells to mediate their retention within the bone marrow parenchyma ([@bib36]). We found that disruption of the SDF-1--CXCR4 axis by the antagonist AMD3100 elicited the release of B cell precursors from bone marrow in control mice but not in B-*S1pr1*KO mice, demonstrating that release of cells to the blood after attenuation of the SDF-1--CXCR4 signal is also dependent on the S1P1 receptor. These results suggest the possibility that an interplay between CXCR4 and S1P1 receptor signals may dictate bone marrow retention or release of the immature B cells into the blood. An interaction between CXCR4-mediated retention and S1P1 receptor--mediated blood release signals has been proposed for the regulation of egress of plasma cells from the spleen ([@bib21]). Interestingly, the synthetic S1P receptor ligand FTY720 modifies CXCR4 signaling on CD34^+^ hematopoietic stem and progenitor cells (HSPCs; [@bib22]; [@bib57]). In addition, a direct interaction between the S1P1 and CXCR4 receptor signaling pathways has been described in HSPCs overexpressing the S1P1 receptor, which inhibits their SDF-1--CXCR4--dependent migration and homing to the bone marrow in vivo by causing down-modulation of CXCR4 expression and signaling ([@bib49]). In the B-*S1pr1*KO mice examined in this study, however, we were unable to find that either CXCR4 expression or chemotaxis to SDF-1 was altered in bone marrow B cells.

In this study, we showed that forced expression of CD69 in bone marrow precursor B cells led to an increase in apoptotic frequency of immature bone marrow B cells and decreased numbers of immature B cells in blood, copying the phenotype of the B-*S1pr1*KO mice. CD69 expression was previously shown to impair egress of maturing T cells from the thymus ([@bib25]; [@bib14]; [@bib35]), and B and T cells from lymph nodes ([@bib53]), by lowering the surface expression of S1P1 receptor through protein--protein complex formation ([@bib53]). We found that CD69 overexpression decreased S1P1 receptor expression in bone marrow B cells of the CD69 transgenic mice, and that CD69 and S1P1 receptor colocalized in intracellular compartments of HEK293 cells. The cellular trafficking pathways involved in the regulation of the S1P1 receptor by CD69 have not yet been determined.

The S1P1 receptor requirement for bone marrow exit extends to other cell types. Osteoclast precursors, which differentiate from the myeloid lineage in the bone marrow, rely on the S1P1 receptor to move from the bone surface into the peripheral blood ([@bib20]). An S1P1 receptor requirement has also been suggested for the regulation of HSPC bone marrow retention and release, and their egress from peripheral tissues ([@bib31]). It will be of interest, and of potential clinical importance, to determine if a dependence on S1P1 receptor signaling extends to other bone marrow cell populations for the control of their emergence in blood as they traffic to peripheral tissues.

MATERIALS AND METHODS
=====================

Mice
----

### B-*S1pr1*KO mice.

We previously generated the *S1pr1^loxP/loxP^* mice ([@bib1]; [@bib2]) carrying the *S1pr1* gene with loxP sequences flanking exon 2, which contains the entire coding region. To specifically delete the S1P1 receptor from B cells, *S1pr1^loxP/loxP^* mice were bred with a *CD19*-driven *Cre* transgenic mouse strain (*CD19-Cre*; [@bib43]). *S1pr1^loxP/loxP^* mice carrying one allele of the *CD19*-*Cre* gene (B-*S1pr1*KO) and littermate *S1pr1^loxP/loxP^* mice (used as controls) were genotyped by PCR using *Cre*-specific primers (cre1, 5′-GCCTGCATTACCGGTCGATGC-3′; cre2, 5′-CAGGGTGTTATAAGCAATCCC-3′). For some experiments, *S1pr1*^loxP/+^ mice were used as controls.

### B cell--specific *CD69* transgenic mice.

The human CD69 cDNA was subcloned downstream of the CAG promoter sequence from the pDRIVE-CAG plasmid (InvivoGen). A cassette containing a loxP-STOP-loxP fragment from pBS302 (Invitrogen) was inserted between the CD69 coding region and the promoter. A linear DNA fragment was prepared and microinjected into the pronucleus of embryos. Potential transgenic mice were screened for the presence of the human *CD69* transgene by PCR analysis of DNA from tail biopsies (forward primer, 5′-GTGGACAAGAAAATGATGCCA-3′; reverse primer, 5′-TGTAACGTTGAACCAGTTGTTAAA-3′) and were bred with mice carrying one allele of the *CD19*-*Cre* gene. Offspring that were positive for the human *CD69* and *Cre* transgenes were tested for the expression of the human CD69 protein on B cells by flow cytometry using an FITC-conjugated anti--human CD69 antibody (BD). Mice lacking the *Cre* or the *CD69* transgene were used as controls.

### *S1pr3* KO mice.

*S1pr3* KO mice were described previously ([@bib23]) and have been backcrossed seven times to C57BL/6 mice.

All animal procedures were approved by the National Institute of Diabetes and Digestives and Kidney Diseases Animal Care and Use Committee and were performed in accordance with National Institutes of Heath guidelines.

### BrdU labeling

For BrdU labeling, mice were injected intraperitoneally once with 200 µl of a 10-mg/ml BrdU solution (BD) and analyzed 48 h later. BrdU^+^ cells were detected using the FITC-BrdU Flow kit (BD) by flow cytometry.

### AMD3100 treatment

B-*S1pr1*KO mice and littermate controls were injected subcutaneously with 100 µl AMD3100 in PBS (5 mg/kg of body weight; Sigma-Aldrich) or PBS alone. After 90 min, cells from the bone marrow, blood, and spleen were obtained and analyzed by flow cytometry.

### Detection of bone marrow sinusoidal and parenchymal B cells

To detect bone marrow sinusoidal and parenchymal B cells, we used an in vivo labeling procedure ([@bib15]; [@bib42]) described by [@bib39]. B-*S1pr1*KO mice and littermate controls were injected intravenously with 1 µg of PE-conjugated anti-CD45.2 antibody (clone 104; eBioscience) in 100 µl PBS. After 2 min, the mice were euthanized and the cells were collected from bone marrow and peripheral blood, and then analyzed by flow cytometry.

### Lymphocyte preparation

Lymphocytes from the bone marrow, spleen, and PLNs (lingual, axillary, brachial, and inguinal) from mice were dissected and mechanically disaggregated. Single-cell suspensions were obtained using a 40-µm cell strainer. Peripheral blood was obtained by cardiac puncture. Red blood cells were removed from blood samples and splenic single-cell suspensions by NH~4~Cl lysis. In some experiments, B cells were isolated from the spleen and bone marrow using anti-B220 magnetic microbeads (Miltenyi Biotec) for RNA analysis. Absolute lymphocyte counts were determined by flow cytometry using counting beads (CALTAG; Invitrogen).

### Flow cytometry and cell sorting

Cells were diluted in 1% BSA-PBS and incubated with anti-FcγR antibody (BD) to block binding of conjugated antibodies to FcγR. Anti--mouse B220 (FITC and PerCP conjugated), anti-IgM (allophycocyanin \[APC\] conjugated), anti-IgD (FITC and PE conjugated), anti-CD43 (PE conjugated), anti-CD69 (FITC conjugated), anti-CD1d (FITC conjugated), anti-CD23 (FITC conjugated), anti-CD21 (PE conjugated), anti-CXCR4 (FITC conjugated), anti-CD3 (PE conjugated), anti-CD93 (biotin conjugated; 493 mAb; [@bib45]), anti-CD49b (FITC conjugated), anti-CD62L (FITC conjugated), anti-CD49d (PE conjugated), and anti-CD11a (PE conjugated) antibodies and PE-conjugated streptavidin were purchased from BD. After cells were labeled with the appropriate antibodies for 30 min on ice and fixed in 1% paraformaldehyde in PBS, they were subjected to flow cytometry on a FACSCalibur or LSR II (both from BD). Data were analyzed using FlowJo software (Tree Star, Inc.).

Bone marrow cells were labeled with anti-B220 (PE-Cy7 conjugated), anti-IgM (APC conjugated), and anti-IgD (FITC conjugated; BD) and sorted into four populations (B220^+^ IgM^−^ IgD^−^, B220^+^ IgM^+^ IgD^−^, B220^+^ IgM^+^ IgD^low^, and B220^+^ IgM^+^ IgD^high^) using a cell sorter (FACSAria II; BD).

### Annexin V labeling of apoptotic cells

Bone marrow cells were stained with anti-B220 and anti-IgM antibodies, washed, and incubated with propidium iodide (PI) or 7-aminoactinomycin D (7-AAD) and annexin V--FITC (BD) for 15 min at room temperature. Cells were analyzed by flow cytometry, and those found positive for annexin V and negative for PI (or 7-AAD) were quantified.

### Immunostaining

12-µm frozen sections of spleens and PLNs were fixed in cold acetone, stained with specific antibodies followed by fluorescently labeled secondary antibodies, and mounted in Vectashield medium (Vector Laboratories). Hamster anti--mouse CD3 and rat anti--mouse B220 antibodies were obtained from BD. FITC-conjugated anti--hamster IgG and Alexa Fluor 594--conjugated anti--rat IgG antibodies (Invitrogen) were used as secondary antibodies. The stained sections were visualized using a fluorescence microscope (DMRXA2; Leica) with 5 and 20× objectives. The images were acquired with a charge-coupled device camera (IEEE1394; Hamamatsu Photonics) using Openlab software (Improvision Inc.)

For immunostaining of the S1P1 receptor in mouse bone marrow cells, IgM^+^ cells were isolated using autoMACS columns (Miltenyi Biotec). The IgM^+^ bone marrow cells were fixed in suspension with methanol at −20°C for 20 min, permeabilized with 50 µg/ml digitonin (Sigma-Aldrich) in PBS for 5 min, and incubated with an anti-S1P1 receptor antibody (Santa Cruz Biotechnology, Inc.) diluted in blocking buffer (3% BSA, 0.1% saponin \[Sigma-Aldrich\] in PBS) for 1 h. Cells were washed with blocking buffer and incubated with a secondary Alexa Fluor 488--conjugated anti--rabbit IgG (Invitrogen). After washing, cells were resuspended in PBS and spun onto a slide using a cytocentrifuge (Shandon Cytospin 3; Thermo Fisher Scientific). Slides were mounted in Vectashield medium and visualized using a fluorescence microscope (DMLD; Leica) with a 40× oil immersion objective. Images were acquired using QCapture software (QImaging Corporation). Cells incubated with only the secondary antibody were used as a negative control.

### Chemotaxis assay

The response of bone marrow B cells toward S1P was studied using 6.5-mm Transwell inserts with a 5-µm pore size (Corning). A bone marrow cell suspension from femurs and tibias (100 µl at 10^7^ cells/ml) in RPMI 1640 plus 0.4 mg/ml fatty acid--free (FAF)--BSA (medium + FAF-BSA; Sigma-Aldrich) was added to each insert in a well containing 600 µl of a solution of S1P (Avanti Polar Lipids, Inc.) or SDF-1 (R&D Systems) prepared in medium + FAF-BSA. Wells containing medium + FAF-BSA without S1P or SDF-1 were used as controls. After 2 h at 37°C, cells in the bottom of the wells were harvested, counted, and analyzed by flow cytometry.

### RT-qPCR

Total RNA was purified from sorted bone marrow B cells using TRI[zol]{.smallcaps} (Invitrogen). The mRNA expression levels of mouse *S1pr1*, *S1pr2*, *S1pr3*, *S1pr4*, and *S1pr5* genes were determined by RT-qPCR using Assay-on-Demand probes and primers (Applied Biosystems) on a Sequence Detection System (ABI Prism 7700; Applied Biosystems). GAPDH mRNA level was used as an internal control.

### Confocal microscopy

HEK293 cells stably expressing human S1pr1-GFP ([@bib27]) were obtained from T. Hla (University of Connecticut Health Center, Farmington, CT). A plasmid containing human *CD69* driven by a CMV promoter was obtained from Origene.

Transient transfections were performed using the TransIT-293 reagent (Mirus Bio) according to the manufacturer\'s instructions. Transfected cells were assayed 16--24 h after transfection. For immunofluorescence staining, cells were fixed with methanol for 5 min at room temperature and washed with PBS containing 0.1% Triton X-100. The cells were then incubated with mouse anti--human CD69 (AbD Serotec) antibody followed by Alexa Fluor 594--conjugated goat anti--mouse IgG (Invitrogen) as secondary antibody.

Confocal laser scanning microscopy analysis was performed with a DuoScan system (LSM 5 LIVE; Carl Zeiss, Inc.) using a 63 × 1.4 NA oil immersion objective. Excitation and filters were as follows: GFP, laser 489-nm line for excitation and emission collected with LP 495-nm filter; Alexa Fluor 594, laser 561-nm line for excitation and emission collected with LP 580-nm filter. Images were acquired using ZEN 2007 software (Carl Zeiss, Inc.).

### Statistical analysis

Statistical significance was determined using the Mann-Whitney or Student\'s *t* test. In all cases, P \< 0.05 was considered statistically significant.

### Online supplemental material

Fig. S1 shows that *CD19-Cre* expression alone does not affect the numbers of immature and mature B cells in blood. Fig. S2 compares the numbers of mature and immature B cells in spleens of control and B-*S1pr1*KO mice. Fig. S3 shows the number of viable bone marrow B cell populations in B-*S1pr1*KO mice. Fig. S4 examines the migration of bone marrow B cells of control and B-*S1pr1*KO mice toward S1P. Fig. S5 illustrates that CD69 down-regulates S1P1 receptor surface expression in HEK293 cells. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20092210/DC1>.
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